WORLD CONGRESS ON Gastrointestinal Cancer


1–4 July 2020

worldgicancer.com

A VIRTUAL EXPERIENCE
In the spirit of progress and advancement, the 2020 ESMO World Congress on GI Cancer will be delivered as a virtual experience. With more than 90 scientific sessions dedicated to improving the lives of patients with GI cancer, this meeting offers important knowledge for everyone involved.

THE CONGRESS CHAIRS
DEDICATED TO DELIVERING UNMATCHED EDUCATION ON THE LATEST ADVANCEMENTS IN GI ONCOLOGY.

CHAIR
Mario Dicato
Luxembourg, Luxembourg

CHAIR
Eric Van Cutsem
Leuven, Belgium

VICE CHAIR
Josep Tabernero
Barcelona, Spain

Register Today
worldgicancer.com
+1.678.242.0906
A Virtual Experience to Continue the Mission

THE MOST IMPORTANT FORUM FOR GI ONCOLOGY EDUCATION WILL BE OFFERED AS A VIRTUAL EXPERIENCE THIS YEAR TO ENSURE CONTINUED ACCESS TO GROUNDBREAKING RESEARCH AND IMPORTANT CLINICAL INSIGHTS.

The Congress will be completely accessible from the comfort of your home via any device—all you need is an internet connection.

Your Virtual Registration includes:

- 4 days of live access to the very latest clinical highlights—including 50+ oral abstract presentations, featuring important data and practice-changing insight
- Access to all sessions traditionally delivered during a face-to-face gathering—plus additional sessions released weekly as an on-demand component of the educational program
- 12-month on-demand access to all educational sessions recorded during the live program as well as to those added once the live program concludes—watch at your convenience
- Engaging exchange through real-time Q&A and discussion with our globally recognized faculty experts
- Beyond the educational program, connect with your global community by participating in independent satellite symposia and networking opportunities, and browsing the exhibit hall.

Visit worldgicancer.com/virtualFAQ to learn more
The Scientific Committee

Composed of some of the world’s leading experts, the Scientific Committee has worked to develop a robust and unmatched scientific program for a critical and comprehensive update in GI cancer.

Monica M. Bertagnolli
Brigham and Women’s Hospital
Boston, United States

Andrés Cervantes
Biomedical Research Institute INCLIVA
University of Valencia
Valencia, Spain

Fortunato Ciardiello
Università degli Studi della Campania Luigi Vanvitelli
Naples, Italy

Mario Dicato
Luxembourg Medical Center
Luxembourg, Luxembourg

Michel P. Ducrœux
Gustave Roussy
Paris, France

Sharlene Gill
BC Cancer - University of British Columbia
Vancouver, Canada

Thomas Gruenberger
Social Medical Center South Vienna
Austria

Karín Haustermans
University Hospital Gasthuisberg
Leuven, Belgium

David H. Ilson
Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, United States

Philipp A. Philip
Karmanos Cancer Institute
Detroit, United States

Rachel P. Riechelmann
AC Camargo Cancer Center
São Paulo, Brazil

Erika Ruiz-García
Instituto Nacional de Cancerología
Mexico City, Mexico

Thomas T. Seufferlein
Ulm University
Ulm, Germany

Josep Tabernero
Vall d’Hebron University Hospital
Barcelona, Spain

Harpreet Wasan
Imperial College Healthcare
London, United Kingdom

Axel Grothey
West Cancer Center
Germantown, United States

Dow-Mu Koh
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom

Ghassan K. Abou-Alfa
Memorial Sloan Kettering Cancer Center
New York, United States

Renê Adam
Université Paris Sud Hôpital Paul Brousse
Villejuif, France

Thierry André
Hospital Saint Antoine
Paris, France

Teresa Amaral
Eberhard Karls University
Tübingen, Germany

Irît Ben-Aharon
Rambam Health Care Campus
Haifa, Israel

Jacques J. Bergman
Academic Medical Center
Amsterdam, Netherlands

Jaume Capdevila
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Andrea Cerca
Memorial Sloan Kettering Cancer Center
New York, United States

Christopher H. Crane
Memorial Sloan Kettering Cancer Center
New York, United States

Christophe Deroose
University Hospital Gasthuisberg
Leuven, Belgium

Rodrigo Dienstmann
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Robert Glynne-Jones
Academic Medical Center
Amsterdam, Netherlands

Sophia Tejpar
University Hospital Gasthuisberg
Leuven, Belgium

Scott Kopetz
MD Anderson Cancer Center
The University of Texas
Houston, United States

Teresa Macarulla
Vall d’Hebron University Hospital
Barcelona, Spain

Vincenzo Mazzaferrro
Istituto Nazionale per i Tumori
Milan, Italy

Markus Möhler
University Medicine of the Johannes Gutenberg-University Mainz
Mainz, Germany

Magnus Nilsson
Karolinska Institutet
Karolinska University Hospital
Stockholm, Sweden

Eileen M. O’Reilly
Memorial Sloan Kettering Cancer Center
New York, United States

Michael Overman
MD Anderson Cancer Center
The University of Texas
Houston, United States

Marianne Pavel
Friedrich-Alexander University Erlangen
Erlangen, Germany

Solange Peters
Lausanne University Hospital
Lausanne, Switzerland

Raquel Perez-Lopez
Vall d’Hebron University Hospital
Barcelona, Spain

Rodrigo Perez
Angelita & Joaquin Gama Instituto Hospital Benfica
Portuguesa de São Paulo
São Paulo, Brazil

Maria Reig
Hospital Clínic de Barcelona
Barcelona, Spain

Alberto F. Sobrero
IRCCS Ospedale San Martino IST
Genoa, Italy

Elizabeth C. Smyth
Cambridge University Hospitals
NHS Foundation Trust
Cambridge, United Kingdom

Zsófia Stadler
Memorial Sloan Kettering Cancer Center
New York, United States

Juan W. Valle
The Christie NHS Foundation Trust
Manchester, United Kingdom

Mark van Berge
London, United Kingdom

Jan van Berge
London, United Kingdom

Chris Verslype
University Hospital Gasthuisberg
Leuven, Belgium

Arndt Vogel
Medizinische Hochschule Hannover
Hannover, Germany

Anna-Dorothea Wagner
Lausanne University Hospital
Lausanne, Switzerland

Zev Wainberg
Ronald Reagan UCLA Medical Center
Los Angeles, United States

John R. Zalcberg
Monash University
Melbourne, Australia

*Confirmed as of May 12.
For the most up-to-date faculty list, please visit worldgicancer.com
Wednesday 1 July 2020

13:00 Welcome and Introduction
13:15 Concurrent Symposia

SESSION I CANCER OF THE PANCREAS AND BILIARY TRACT
14:15 Presentation of Selected Abstracts on Biliary Tract and Pancreatic Cancers
16:24 Live Q&A With Key Opinion Leaders
16:44 Break
17:00 Concurrent Symposia
18:00 KEYNOTE: New Agents on the Horizon in Metastatic Disease (Biliary Duct and Pancreatic Cancer)

SESSION II HEPATOCELLULAR CANCER
18:20 Presentation of Selected Abstracts on Hepatocellular Cancer
19:58 KEYNOTE: How to Integrate New Agents in HCC
20:18 Live Q&A With Key Opinion Leaders
20:38 Break
16:40 KEYNOTE: Checkpoint Inhibition in Esophageal and Metastatic Gastric Cancer
17:00 Concurrent Symposium
18:00 KEYNOTE: New Agents on the Horizon in Esophageal and Gastric Cancer

Thursday 2 July 2020

13:00 Welcome and Introduction; Highlights of Day 1
13:15 Concurrent Symposia

SESSION III ESOPHAGEAL AND GASTRIC CANCER
14:15 Presentation of Selected Abstracts on Gastric Cancer
15:58 Live Q&A With Key Opinion Leaders
16:18 Break
16:40 KEYNOTE: Checkpoint Inhibition in Esophageal and Metastatic Gastric Cancer
17:00 Concurrent Symposium
18:00 KEYNOTE: New Agents on the Horizon in Esophageal and Gastric Cancer

SESSION IV GASTROINTESTINAL STROMAL TUMORS (GIST); NEUROENDOCRINE TUMORS (NET)
18:20 Presentation of Selected Abstracts

SESSION V MOLECULAR SCREENING; IMAGING; ARTIFICIAL INTELLIGENCE
18:50 Presentation of Selected Abstracts
19:00 DISCUSSANT/Lecture: Early Detection of Cancer in the Normal Population
19:24 DISCUSSANT/Lecture: Artificial Intelligence and Machine Learning in Cancer Imaging
19:39 Presentation of Selected Abstracts
19:46 DISCUSSANT/Lecture: Radiomics in Imaging
20:01 Live Q&A With Key Opinion Leaders
20:21 Adjourn
Saturday
4 July 2020

12:00
Welcome and Introduction; Highlights of Day 3

12:15
Concurrent Symposia

SESSION VIII
KEYNOTE PRESENTATIONS I

13:15
KEYNOTE: Women in Oncology

13:35
KEYNOTE: COVID-19 and Cancer

SESSION IX
RECTAL CANCER

13:55
Presentation of Selected Abstracts

14:24
KEYNOTE: Total Neoadjuvant Treatment in Rectal Cancer: Reality or Myth?

14:44
Live Q&A With Key Opinion Leaders

SESSION X
KEYNOTE PRESENTATIONS II

15:04
KEYNOTE: Harmful Drug Interactions in GI Oncology

15:24
KEYNOTE: Relevant Pathways in Immuno-Oncology

15:44
Break

16:10
Concurrent Symposium

SESSION XI
POSTER DISCUSSIONS

17:10
HCC/Biliary Tract Cancer

17:20
Pancreatic Cancer

17:30
Colon Cancer

17:40
Other

17:50
Live Q&A With Key Opinion Leaders

18:10
Adjourn

Friday
3 July 2020

12:00
Welcome and Introduction; Highlights of Day 2

12:15
Concurrent Symposia

SESSION VI
COLORECTAL CANCER I

13:15
Presentation of Selected Abstracts on Colorectal Cancer

15:40
Live Q&A With Key Opinion Leaders

16:00
Break

16:10
Concurrent Symposia

SESSION VII
COLORECTAL CANCER II

17:30
Presentation of Selected Abstracts on Colorectal Cancer

20:10
Live Q&A With Key Opinion Leaders

20:30
Adjourn
IMPACT OF PATIENT FACTORS IN DISEASE BIOLOGY IN GI CANCER: GENDER AND AGE

The Explosion of CRC (or GI Cancer) in Young Adults: Why?
Why Does Gender Matter for Treatment?

RELEVANT PATHWAYS IN GI CANCER: HOW RELEVANT AND HOW TO APPROACH THEM

The HER2 Pathway in GI Cancer
FGFR and Other Fusions in GI Cancer
Should DPD Deficiency Be Tested Before Starting 5FU?
How to Interpret an NGS Sequencing Report
Debate: Tumor or Liquid Biopsies in the Future?

KEYNOTE PRESENTATIONS

KEYNOTE: Integrating Health Economic Evaluation into Daily Practice in the COVID-19 Era

HEPATOCELLULAR CANCER

Can We Maximize the Benefit of IO in HCC?
Locoregional Treatment in HCC
Liver Transplantation in the COVID-19 Era

MULTIMODALITY THERAPY FOR RECTAL CANCER

Neoadjuvant Treatment: How and for Whom?
Organ Preserving Strategy
Local Excision (TEM/TAM) vs. Radical Resection: When and in Whom?
Case Presentations

EXPANDED ON-DEMAND PROGRAMME

In addition to our live scientific programme, a 13-session, 15.6-hour expanded on-demand programme will be included in your registration. This programme will release therapy focused sessions over a period of several weeks following the virtual broadcast.

CANCER OF THE PANCREAS AND BILIARY TRACT

Hereditary Pancreatic Cancer: Genetics and Surveillance
Targeting the Microenvironment and the Immune System
How to Integrate and Interpret Best Imaging in Locally Advanced PDAC and What to Use for Response Evaluation: EUS, PET/CT, MRI
Debate: Neoadjuvant Treatment for Resectable Pancreatic Cancer
Treatment Modalities for Locally Advanced Pancreatic Cancer (Including SBRT, Ablation)
The Actual Algorithm in Advanced PDAC: A Strategic Approach (Covering Later Lines, PARP)
Druggable Molecular Alterations in Bile Duct Cancer
Locally Advanced Bile Duct Cancer

PROGRESS IN GI CANCER

How Can Consortia Contribute to the Progress in GI Oncology?
Contribution of the ARCAD Group
Contribution of the ACCENT Group
Teaching and Interpreting Statistics for Clinicians
Reporting on Endpoints: The Example in CRC
Debate: Neoadjuvant Treatment for Rectable Pancreatic Cancer

ESOPHAGEAL AND GASTRIC CANCERS

When and How to Treat Early Esophageal Cancer Endoscopically (Covering EMR, ESD, RFA)
Debate: GEJ Cancer: Locally Advanced Perioperative CT or Preoperative CRT
Adjuvant Treatment After Preoperative CRT in Esophageal or GEJ Cancer: When and How
Interaction Between Neoadjuvant Therapies, Comorbidity, and Surgery

GASTRIC CANCER

Treatment Algorithms in Metastatic Gastric Cancer
New HER2-Directed Agents in Gastric Cancer
Exhibition Experience

An innovative virtual Exhibition offers Congress participants a unique and interactive opportunity to engage with industry representatives to discover the latest approaches to treatment and groundbreaking medical technologies focused on treating patients with gastrointestinal cancers.

The ESMO World Congress on GI Cancer is part of the Oncology Learning Network.

Visit Oncology Learning Network, the digital home of ESMO World Congress on GI Cancer, for exclusive access to session abstracts, multimedia interviews with key opinion leaders, and news coverage of this year’s event and more at www.oncnet.com
Continuing Education

ESMO-MORA

The Congress programme will be submitted for ESMO-MORA category 1 points accreditation. Re-certification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and possesses the necessary skills and standards for the practice of medical oncology.

Who Should Attend

This Congress is specifically designed for practicing clinicians, gastroenterologists, hepatologists, pathologists, surgeons, medical oncologists, radiation oncologists, and clinical researchers who wish to review and update their knowledge and management of cancers of the gastrointestinal tract.

Learning Objectives

After attending this Congress, participants should be able to:

- Identify current controversies in the management of patients with gastric or esophageal cancers
- Discuss contemporary treatment options for patients with gastric or esophageal cancers
- Comment on available treatment options for rare gastrointestinal and neuroendocrine tumors
- Describe the epidemiology and pathogenesis of hepatocellular carcinoma
- Discuss management of patients with liver cancer
- Identify adjuvant and neoadjuvant treatment options for patients with locally advanced and metastatic cancer of the pancreas
- Select the most appropriate detection, screening, and chemoprevention methods for colorectal cancer
- Describe the use of molecular markers for screening and prognosis of colorectal cancer and gastric cancer
- Select the most appropriate adjuvant and neoadjuvant treatments for colorectal cancer patients
- Comment on new agents in the treatment of colorectal cancer and the latest clinical trials results
- Identify treatment strategies for rectal cancer
- Distinguish appropriate surgical techniques for the treatment of gastrointestinal cancer

Registration

Groups

Groups of 10 or more should register by contacting the registration team directly at registration@imedex.com to complete the Group Registration Form.

<table>
<thead>
<tr>
<th>ESMO Member</th>
<th>Registration Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>€ 399</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€ 239</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant</td>
<td>€ 59</td>
</tr>
<tr>
<td>Pharmaceutical Industry Representative</td>
<td>€ 649</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Non-ESMO Member</th>
<th>Registration Rates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician</td>
<td>€ 499</td>
</tr>
<tr>
<td>PhD, PharmD</td>
<td>€ 299</td>
</tr>
<tr>
<td>Nurse, Student, Trainee, Fellow, Resident, Nurse Practitioner, Physician Assistant</td>
<td>€ 79</td>
</tr>
<tr>
<td>Pharmaceutical Industry Representative</td>
<td>€ 649</td>
</tr>
</tbody>
</table>

Register online at worldgicancer.com

Call +1 678.242.0906
Email: registration@imedex.com

Register Today and Save | worldgicancer.com +1.678.242.0906